UCB 0942

Drug Profile

UCB 0942

Alternative Names: UCB0942

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Epilepsy

Most Recent Events

  • 13 Aug 2015 UCB initiates enrolment in a phase II extension trial for Epilepsy (Treatment-resistant) in Netherlands (EudraCT2015-001268-20)
  • 01 Jul 2015 Phase-II clinical trials in Epilepsy (Treatment-resistant) in Germany (PO) after July 2015
  • 01 Jul 2015 Phase-II clinical trials in Epilepsy (Treatment-resistant) in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top